FRANCE UP CLOSE: Can you sell your CE-marked device in French overseas territories?
This article was originally published in Clinica
Executive Summary
You have CE marked your medical device or in vitro diagnostic product, and produced the labelling in French. But are these steps then sufficient to allow you to market your products throughout the French territories that lie outside France and indeed outside Europe? In the first instalment of Clinica’s new series focused on issues specific to Europe’s second largest medtech market, Alexandre Regniault* and Damien Bertier* explain the legalities of selling your product in French overseas territories and aim to provide some practical answers
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.